Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Iambic Therapeutics, Inc. (IAM)

Iambic Therapeutics adopts restated charter and bylaws as IPO completes

Neutral Impact 2 of 5 shareholder Written later

Iambic Therapeutics filed an amended and restated certificate of incorporation and adopted amended and restated bylaws on October 16, 2026, in connection with completing its initial public offering. The filing refers to the prospectus filed October 15, 2026 for the full description of the new governing documents, which set out the company's shareholder framework now in effect.

Key points

  • Restated Certificate of Incorporation filed with Delaware Secretary of State on October 16, 2026, tied to the IPO completion
  • Restated Bylaws adopted effective October 16, 2026, described in the October 15, 2026 final prospectus
  • Item 7.01 notes the company may use its website, social media and other channels to disclose material information

The filing

CompanyIambic Therapeutics, Inc. (IAM)
Form8-K, current report
Filed with the SECOct 16, 2026, 5:03 PM ET
Accession number0001193125-26-424242

Items reported: 5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.